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Abstract. Two new platinum(IV) complexes of 3-aminocyclohexanespiro-5-hydantoin (achsh) and 
3-aminocycloheptanespiro-5-hydantoin (achpsh) were prepared and characterized. Ab initio calculation of the 
structure and the measurements of IR and NMR spectra of complexes were also performed. The complex-
es were evaluated for in vitro cytotoxicity in murine erythroleukemia (MEL) cells, clone F4N. The com-
plexes exerted low in vitro toxicity, comparable with that of the corresponding platinum(II) complexes.  
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INTRODUCTION 
The use of cis-diamminedichloroplatinum(II), known as 
cisplatin or cis-DDP in cancer chemotherapy has a ma-
jor impact on some tumor types, such as testicular or 
ovarian carcinoma.1 However, cisplatin has two major 
drawbacks: 1) severe toxicity that includes nephrotox-
icity, neurotoxicity and ototoxicity and 2) the acquisi-
tion or presence of resistance to the drug.2 Because 
tumor resistance to cisplatin limits its efficacy, there is 
urgent need for new platinum complexes capable of 
overcoming cisplatin resistance. One of the approaches 
to overcome the acquired resistance to cis-DDP is to use 
PtIV complexes. There exist several PtIV complexes such 
as tetraplatin Pt(dach)Cl4 (dach, diaminocyclohexane); 
iproplatin Pt(ipa)2(OH)2Cl2 (ipa, isopropylamine) and 
JM216 Pt(NH3)(cha)(OAc)2Cl2 (cha, cyclohexylamine) 
which recently became very promising antitumor 
agents.1,3 It is widely believed that reduction to plati-
num(II) is essential for the anticancer activity of plati-
num(IV) complexes. There are a number of factors to 
consider when assessing the possible effects of adminis-
tering the PtIV analogue of a PtII complex. The kinetic 
inertness of PtIV complexes offers an increased ability of 
the compounds to arrive the cellular targets intact. Mod-
ifying the axial ligands of platinum(IV) complexes 
alters the solubility of the complex and thus the ability 
to enter tumor cells before being reduced to yield the 
active platinum(II) drug.3 Another advantage of PtIV 
complexes is that some of them could be orally adminis-
tered. In the present work, we report the synthesis 
and characterization of two platinum(IV) complexes of 
3-aminocyclohexanespiro-5-hydantoin and 3-aminocy-
cloheptanespiro-5-hydantoin. The in vitro inhibitory 
effect of the complexes on the growth of murine eryt-
hroleukemia (MEL) cells, clone F4N in culture was 
studied.  
3-Aminocyclohexanespiro-5-hydantoin and 3-Amino-
cycloheptanespiro-5-hydantoin contain  NH2 group with 
excellent coordination properties, and it has been found 
that the activity increases with introducing amino group 
in the hydantoin ring.4 A relatively small number of 
platinum complexes with hydantoins as ligands have 
been synthesized yet.5 The present paper is an extension 
of our previously reported results6,7 for PtII complexes 




K2[PtCl4] was prepared according to Spassovska et al.
8 
The ligands, 3-aminocyclohexanespiro-5-hydantoin (achsh) 
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and 3-aminocycloheptanespiro-5-hydantoin (achpsh) were 
synthesized from cyclohexanone and cycloheptanone to 
cyclohexanespiro-5-hydantoin and cycloheptanespiro-5-
hydantoin respectively, following the Bucherer-Lieb 
reaction.9 After that cyclohexanespiro-5-hydantoin and 
cycloheptanespiro-5-hydantoin were transformed into 3-
aminocyclohexanespiro-5-hydantoin and 3-aminocyclo-
heptanespiro-5-hydantoin by means of NH2NH2.H2O.
10 
The remaining reagents and solvents were AR grade 
products. 
Preparation of the Complexes 
The procedures for preparation of PtIV complexes of 
achsh and achpsh were analogous to those described by 
Hambley et al.11 The PtIV complexes were synthesized 
by oxidation of PtII complexes [Pt(achsh)2Cl2] and 
[Pt(achpsh)2Cl2] with 30 % hydrogen peroxide. 
[Pt(achsh)2Cl2(OH)2] (1). To a suspension of 0.170 g 
(0.27 mmol) of [Pt(achsh)2Cl2] in 20 ml acetone  were 
added 0.5 ml of 30 % H2O2. The reaction mixture was 
refluxed for 20 min after that the solution was filtered. 
The solvent was removed under vacuum and the 
re-sulting oil was precipitated with anhydrous diethyl 
ether. The precipitated product was removed from 
the suspension by filtration and vacuum dried. Yield: 
0.05 g (28 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C16H28N6Cl2O6Pt (Mr = 666.41) are: C 28.84, H 4.23, 
N 12.61, Cl 10.64, Pt 29.27; Found: C 28.40, H 3.78, N 
12.15, Cl 10.87, Pt 29.63. 
[Pt(achpsh)2Cl2(OH)2] (2). To a suspension of 0.200 g 
(0.30 mmol) of [Pt(achpsh)2Cl2] in 30 ml acetone 0.7 ml 
of 30 % H2O2 were added. The reaction mixture 
was refluxed for 30 min and then the solution was 
filtered. The solvent was removed under vacuum and 
the resulting oil was precipitated with anhydrous diethyl 
ether. The precipitated product was removed from 
the suspension by filtration and vacuum dried. Yield: 
0.05 g (24 %). 
Anal. Calcd. mass fractions of elements, w/%, for 
C18H32N6Cl2O6Pt (Mr = 694.46) are: C 31.13, H 4.64, 
N 12.10, Cl 10.21, Pt 28.09; Found: C 31.60, H 4.81, 
N 11.66, Cl 10.62, Pt 28.58. 
Analyses and Physical Measurements 
The elemental analyses were performed by routine mi-
croanalytical techniques (Department of Chemistry, 
Sofia University). 1H NMR spectra were registered on a 
Bruker WM 250 spectrometer at 250 MHz in DMSO-d6 
solution using TMS as internal standard. Infrared spec-
tra were recorded on a Bruker IFS-113V spectrophoto-
meter in CsI disks (4000–150 cm–1). 
Quantum-chemical Calculations 
The ab initio calculations were carried out using the 
GAMESS program package.12 The structure optimizations 
for the [Pt(achsh)2Cl2(OH)2] and [Pt(achsh)2Cl2] com-
plexes were performed at the RHF level without any 
symmetry constrains. The mean gradient threshold was 
0.0001 hartree/Bohr. The calculations were carried out 
with the Stewens-Basch-Krauss-Jasien effective core 
potentials (ECP) and their concomitant basis sets for all 
the atoms (ECP-31G).13,14 The vibrational analysis of 
the obtained structures was carried out. The calculated 
wavenumbers of all normal modes were scaled by a 
factor of 0.91. 
Incubation with Drugs and In Vitro Cytotoxicity Test 
MEL cells, clone F4N (virus-transformed erythroid 
precursor cells)15 were cultured in Dulbecco's modified 
Eagle medium (Gibco, Grand Island, NY) supplemented 
with 10 % calf serum, under 5 % CO2 atmosphere at 
37 °C, and passed every day at a concentration of 5×105 
cells/ml. 
The complexes were dissolved immediately before 
use in DMSO to obtain stock solutions of different con-
centrations. Each of these solutions was used at 1 % 
concentration in the experiments with F4N cells. The 
final concentration of DMSO in the medium did not 
affect cell growth. 
Exponentially growing cells (5×105 cells/ml) were 
incubated in triplicate with increasing concentrations of 
the test complexes in 96-well microtiter plates. After 24, 
48 and 72 h of drug treatment, the cells were counted 
hemocytometrically. The number of dead cells was 
determined by staining with trypan blue. The mean of 
triplicate determinations of three independent experi-
ments was calculated. The 50 % inhibitory dose (IC50) 
was defined as drug concentration that reduces the 
number of living cells by 50 %. 
 
RESULTS AND DISCUSSION 
The complexes are dark yellow coloured solids, stable 
at normal conditions, but decomposing upon heating. 
They are soluble in DMF and DMSO, and slightly so-
luble in water. 
Infrared spectra 
The IR spectral data of the ligand and complexes are 
collected in Table 1. The absorption bands in the range 
of 4000–600 cm–1 belong to the absorptions of 
the organic ligand. The absorption bands in the far 
IR below 600 cm–1 characterize the Pt–OH bonding as 
well as the ligand-metal bonding. The bands in the
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range of absorptions of the N–H stretching vibrations in 
the spectra of complexes were shifted (about 10–30 cm–1) 
to lower frequency as compared to those of the free 
ligand. This is indicative for coordination through the 
NH2 group.
16 The existence of two absorption bands for 
the Pt–Cl stretching vibrations (in the range of 331–348 
cm–1) in the far IR spectra is an indication of the cis-
configuration of the complexes.6,17,18 The weak bands in 
the range of 519–512 cm–1 in the spectra of the com-
plexes could be ascribed to Pt–N stretching vibra-
tions.17,18,19 The presence of absorption bands in 551 
cm–1 and 590 cm–1 respectively  is due to the Pt–O stret-
ching vibrations17,18 and it is indicative of the oxidation 
to PtIV. Ab initio calculated characteristic vibrations for 
Pt–O, Pt–N and Pt–Cl bonds of the compound shown in 
Figure 2 are in good agreement with experimental data 
listed in Table 1. 
1H NMR spectra 
The 1H NMR spectral data for freshly prepared DMSO-d6 
solutions of the ligands and complexes are presented in 
Table 2. In the spectra of the 3-aminocyclohexanespiro-
5-hydantoin and 3-aminocycloheptanespiro-5-hydantoin 
were observed complicated multiplets in the range of 
1.21–1.83 ppm due to the methylene protons at the 
cycloalkane rings. Signals for NH2 groups were regis-
tered at 4.62 ppm and 4.64 ppm. For the NH groups 
signals were found at 8.50 ppm and 8.40 ppm, respec-
tively. In the spectra of the complexes, the signals of 
the NH2 protons were significantly shifted downfields 
(average 2.83 ppm) in comparison to the free ligand.
The signals of NH protons were much less affected 
(average 0.27 ppm). In our previous work with PtII 
complexes,16 analogous effects have been described. 
A downfield shift of the same order has been registered 
for the proton signals of coordinated NH2 groups in the 
spectra of a number of PtII amine complexes.21 That is a 
reason to consider that in our complexes the amino-
ligands coordinate to platinum via the NH2 group. The 
signals of NH2 and NH protons of the studied complexes 
were accompanied by some weaker peaks. These addi-
tional signals can be explained by solvolysis products of 
the complexes in DMSO.22 In the spectra of the plati-
num complexes no significant shift of the signals due to 
the cyclohexane residue was registered. Similar IR and 
1H NMR spectral data have been reported in our pre-
vious papers for platinum complexes of differently 
substituted cycloalkanecarboxylic acid hydrazides.6, 7, 16 
The elemental analysis and spectroscopic data 
confirm the structures of the complexes shown in Figure 1.
Table 1. IR data for the ligands and complexes 
No Compound 
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*Abbreviations: s, strong; m, medium; w, weak; sh, shoulder. Ab initio calculated data are given in brackets (asym, sym) 




CH2  NH2   NH 
 achsh 1.21-1.66 m 4.62 s 8.50 s 
1 [Pt(achsh)2Cl2(OH)2] 1.41-1.82 m 7.64 8.75 
 achpsh 1.54-1.83 m 4.64 s 8.40 s 
2 [Pt(achpsh)2Cl2(OH)2] 1.54-1.97 m 7.27 8.69 
*Abbreviations: s, singlet; m, multiplet. 
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Quantum-chemical Data 
The ab initio calculated structure of the complexes 
[Pt(achsh)2Cl2(OH)2] and [Pt(achsh)2Cl2] are shown in 
Figure 2, and the most important bond lengths and bond 
angles are listed in Table 3. The cyclohexane moiety 
does not lead to changes of the structure of the 
complex.6 For that reason we consider theoretically 3-
amino-hydantoin as ligand in the complexes 
[Pt(achsh)2Cl2(OH)2] and [Pt(achsh)2Cl2]. 
The Pt–Cl and Pt–N bonds in [Pt(achsh)2Cl2] are 
in agreement with the available experimental data,23 
(Table 3). The ab initio calculated Pt–Cl and Pt–N 
bonds are 0.065 Å and 0.092 Å longer, respectively, 
than experimental values presented in the Table. In the 
PtIV complex the Pt–Cl bond shortens by 0.025 Å and 
Pt–N bond becomes shorter by 0.034 Å than respective 
bonds in the PtII complex (Table 3). 
The square planar coordination geometry around 
the Pt atom consists of two cis chlorine atoms and two 
nitrogen atoms from amino group of hydantoin mole-
cule. The first hydantoin fragment is situated over the 
plain of the complex and the second – under the plain. 
Cytotoxic Effect 
The growth-inhibitory effect of the ligands achsh and 
achpsh and their two platinum(IV) complexes on F4N 
cells in culture was examined. The results, as expressed 
by IC50 values for different times of drug exposure, are 
presented in Table 4. The complexes were low inhibitory 
towards F4N cells, resembling the activity of the 
corresponding PtII complexes, as reported earlier.6,7 
Up to the concentration of 100 µmol L–1 they exhibited 
rather cytostatic than cytotoxic effect. Nevertheless, 
 
































Table 3. Important ab initio calculated bond lengths /Å and 
bond angles /deg for the complexes [Pt(achsh)2Cl2(OH)2] (1) 
and [Pt(achsh)2Cl2] (2), shown in Figure 2 
Parameter 1 2 Experimental(a) 
Bond    
Pt–Cl 2.352 2.377 2.315(b) (2.312(c))
Pt–N 2.118 2.152 2.065(b) (2.060(c))
Pt–O 1.999  1.987(b) 
O–H 0.965   
Bond angle    
Cl–Pt–N 88.3 84.9 90.7(c) 
Cl–Pt–Cl 91.8 95.4 89.8(c) 
N–Pt–N 91.7 95.0 89.5(c) 
Cl–Pt–O 93.3   
(a)X-ray data: (b) Ref. 20, (c) Ref. 21 
 
Figure 2. Ab initio calculated structure of the complexes
[Pt(achsh)2Cl2(OH)2] (1) and [Pt(achsh)2Cl2] (2). For simplici-


















































Table 4. Cytotoxicity of platinum complexes in F4N cells 
No Compound 
IC50
(a) /mol L–1 
24 h(b) 48 h(b) 72 h(b) 
 achsh  (c)  
1 [Pt(achsh)2Cl2(OH)2] 260 247 211 
 [Pt(achsh)2Cl2]
(e) (d) (c) (c) 
 achpsh  (c)  
2 [Pt(achpsh)2Cl2(OH)2] 237 159 133 
 [Pt(achpsh)2Cl2]
(f) (c) 280 (c) 
 Cisplatin 5.8 4.9 3.9 
(a) Drug concentration reducing the number of living cells by 50 %. 
(b) Time of drug treatment. 
(c) No inhibition of cell growth at concentrations up to 200 μmol L–1. 
(d) 25 % inhibition of cell growth at concentration of 100 μmol L–1. 
(e) Ref. 6. 
(f) Ref. 7. 
Values are mean of triplicate determinations in two independent 
experiments. 
1                                                2 
1                                            2 
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complex 2 proved to be more active than complex 1, 
reducing upon 72 h incubation the number of living cells 
by more than 90 %. The ligands did not show any inhibi-
tory activity up to the concentration of 200 µmol L–1. 
We assume that in the cell, PtIV complexes undergo 
a rapid reduction to the respective PtII compounds thus 
displaying the reduced activity of the latter complexes. 
It would be of interest to synthesize and study trans-PtIV 
complexes with 3-aminocyclo-hexanespiro-5-hydantoin 
and 3-aminocycloheptanespiro-5-hydantoin as well 
as PtIV complexes containing mixed-amino (NH3 and 
3-aminocycloalkanespiro-5-hydantoin) ligands. Recent 
data indicate that such compounds could exert retarded 
in vivo reduction and increased activity against cis-
platin-resistant tumor cells.24 
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SAŽETAK  
Sinteza, struktura i citotoksičnost kompleksa platine(IV) s 
3-Aminocikloheksanspiro-5-hidantoinom 
i 3-Aminocikloheptanspiro-5-hidantoinom 
Daniel Kushev,a Venelin Enchev,b Emilya Naydenova,c Roumiana Detcheva,a 
Nadejda Spassovskaa i Konstantin Grancharova   
aInstitute of Molecular Biology, Bulgarian Academy of Sciences, BG-1113 Sofia, Bulgaria  
bInstitute of Organic Chemistry, Bulgarian Academy of Sciences, BG-1113 Sofia, Bulgaria  
cDepartment of Organic Chemistry, Chemical Technology and Metallurgy University, BG-1756 Sofia, 
Bulgaria  
Pripravljena su i opisana dva nova kompleksa platine(IV) s 3-aminocikloheksanspiro-5-hidantoinom (achsh) i  3-
aminocikloheptankspiro-5-hidantoinom (achpsh). Također su obavljeni i Ab initio proračuni strukture, kao i mjerenja 
IR i NMR spektara kompleksa. Citotoksičnost kompleksa procjenjena je in vitro na stanicama eritroleukemije mu-
rine  (MEL), klon F4N. Kompleksi ispoljavaju nisku in vitro toksičnost, usporedivu s onom odgovarajućih kom-
pleksa platine(II). 
